Arrhythmia Research Technology, Inc.
http://www.arthrt.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arrhythmia Research Technology, Inc.
Sanofi’s Orbis-Approved GVHD Drug Rezurock Rejected For English Funding
NICE has provisionally turned down three products for funding under the National Health Service in England: Sanofi’s Rezurock for chronic graft-versus-host disease, Sobi’s lymphoma drug Zynlonta, and AstraZeneca/Daiichi Sankyo’s Enhertu for the new indication of HER2-low breast cancer.
AstraZeneca/Daiichi Sankyo’s Enhertu To Get Lung Cancer Label For EU
The European Medicines Agency has recommended new uses for 11 approved medicines, including an antibody drug conjugate for treating advanced non-small cell lung cancer.
Lebrikizumab Among Nine Drugs To Get EMA Nod; PTC Faces Disappointment For Translarna
The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs.
Bayer Heralds Potential Of BlueRock Parkinson's Stem Cell Therapy
Bayer pharma research head Christian Rommel has told Scrip he was excited about the Phase I data on Parkinson's disease prospect bemdaneprocel, which is comprised of dopamine-producing neurons derived from pluripotent stem cells, but also advocated caution at this early stage.
Company Information
- Industry
- Medical Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice